Oncolytics Biotech (ONCY) EBITDA Margin (2009 - 2020)
Oncolytics Biotech (ONCY) posted quarterly EBITDA Margin of 16.33% for Q3 2020, up 495.0% year-over-year from 2.74% in Q4 2019, and down 12.6% quarter-over-quarter from 14.5% in Q2 2020.
Oncolytics Biotech (ONCY) EBITDA Margin (2009 - 2020) Analysis & Trends
Oncolytics Biotech (ONCY) has reported EBITDA Margin for 7 consecutive years, with 16.33% the latest figure, recorded in Q3 2020.
- In Q3 2020, EBITDA Margin rose 495.0% year-over-year to 16.33%; the TTM figure through Sep 2020 stood at 16.18% (down 1618.0% YoY), while the FY2018 annual figure was 0.0%, changed N/A from the prior year.
- EBITDA Margin declined to 16.33% in Q3 2020 per ONCY's latest filing, from 14.5% in the prior quarter.
- Across five years, EBITDA Margin topped out at 18650.71% in Q3 2018 and bottomed at 34.58% in Q2 2019.
- Historically, EBITDA Margin has averaged 2103.59% across 5 years, with a median of 0.0% in 2017.
- Annual changes were most pronounced in 2019 — EBITDA Margin slumped 1867199 bps — and 2020, when it soared 2007 bps.
- Oncolytics Biotech's EBITDA Margin stood at 368.32% in 2016, then slumped by 100 bps to 0.0% in 2017, then soared by 104 bps to 0.0% in 2018, then plunged by 67724626 bps to 21.28% in 2019, then climbed by 23 bps to 16.33% in 2020.
- Business Quant data shows ONCY's EBITDA Margin at 16.33% in Q3 2020, 14.5% in Q2 2020, and 21.28% in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.75% |
| 10 | Oncolytics Biotech | 98.53 Mn | 98.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -16.33% |
| Jun 30, 2020 | -14.50% |
| Sep 30, 2019 | -21.28% |
| Jun 30, 2019 | -34.58% |
| Mar 31, 2019 | 0.00% |
| Dec 31, 2018 | 0.00% |
| Sep 30, 2018 | 18,650.71% |
| Jun 30, 2017 | 0.00% |
| Jun 30, 2016 | 368.32% |
| Jun 30, 2010 | 1,403.86% |
| Dec 31, 2009 | -5,228.79% |
| Sep 30, 2009 | 26.31% |
| Jun 30, 2009 | 33.98% |
| Mar 31, 2009 | 40.38% |